NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MediWound Ltd. (MDWD) Stock Analysis

MediWound Ltd. (MDWD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MDWD

$13.29

+$0.08 (+0.61%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MDWD with… →

MDWD Key Statistics

As of Sep 4, 2026
Trading
Open
$13.13
Previous Close
$13.21
Day's Range
13.03–13.41
52-Week Range
12.52–20.30
Volume
86.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.14
Valuation
Market Cap
$171.58M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.46
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.17
Financials (FY)
Revenue (FY)
$16.96M−16.14%
Net Income (FY)
−$23.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
−170.10%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.91M
1-Year Return
−20.70%
Dividend and dates
Earnings Date
November 19, 2026
Avg Volume
84.47K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MDWD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.01%
2025+3.71%
2024+75.02%
2023−24.61%
2022−18.34%
2021−36.22%
2020+19.35%
2019−23.65%
2018−8.76%
2017−2.82%
2016 (partial year)−34.59%

As of September 4, 2026.

MDWD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.96M−$23.88M−140.8%
2024$20.22M−$30.22M−149.5%
2023$18.69M−$6.72M−35.9%
2022$26.50M−$19.60M−74.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.96M$3.25M−$25.28M−$23.88M−140.8%
2024$20.22M$2.63M−$19.38M−$30.22M−149.5%
2023$18.69M$3.58M−$15.50M−$6.72M−35.9%
2022$26.50M$13.17M−$7.66M−$19.60M−74.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MDWD Valuation vs Biotechnology Median

Median of 656 stocks
MetricMDWDBiotechnology medianvs median
P/S ratio14.4615.265% below
Profit margin−170.10%0.00%170.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MediWound Ltd. (MDWD) carries a market capitalisation of $171.58M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 121 employees.

Over the past 52 weeks the price has ranged from $12.52 to $20.30. The most recent close on file for MDWD is $13.29, dated September 4, 2026. That is +$0.08 (+0.61%) against the previous close. The latest close sits 6.15% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $16.96M. Against the prior fiscal year total of $20.22M, that is a change of −16.14%. The same year closed with a net loss of $23.88M. The reported profit margin is −170.1%. That is 170.1 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −2.17.

Across the 4 fiscal years on file, revenue moves from $26.50M in 2022 to $16.96M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 14.46 times revenue. On price-to-sales that is 5.24% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.14. Annualized volatility over the trailing 10 years is 60.26%. Over the trailing twelve months the price has returned −20.70%. Across 10 years the annualized return works out at −12.81%.

Growth & Income

The record shows no dividend for MDWD.

The strongest complete calendar year on file is 2024 at +75.02%; the weakest is 2021 at −36.22%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −28.01% year to date.

Peer Comparison

MediWound Ltd. (MDWD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MediWound Ltd. MDWD $171.58M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MediWound Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Visit website →